Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | malignant peripheral nerve sheath tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | malignant peripheral nerve sheath tumor | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, Keytruda (pembrolizumab) treatment resulted in complete metabolic response after 4 cycles of treatment in a patient with CD274 (PD-L1)-positive malignant peripheral nerve sheath tumor, and the patient stayed on treatment for 21 cycles (PMID: 31383651). | 31383651 |
PubMed Id | Reference Title | Details |
---|---|---|
(31383651) | PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. | Full reference... |